OSR Health, Inc. (OSRH)
| Market Cap | $4.94M-71.5% |
| Revenue (ttm) | $1.71M |
| Net Income | -$10.22M |
| EPS | -$0.37 |
| Shares Out | 35.26M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 152,945 |
| Open | $0.09 |
| Previous Close | $0.10 |
| Day's Range | $0.07 - $0.16 |
| 52-Week Range | $0.05 - $0.90 |
| Beta | n/a |
| Analysts | none |
| Price Target | $10.00(+7042.86%) |
| Earnings Date | n/a |
About OSRH
OSR Health, Inc., a healthcare holding company, develops a portfolio of therapies and healthcare solutions in the United States, Europe, and Korea. The company develops immunotherapy products, including VXM01, an immuno-oncology candidate for glioblastoma completed phase 2 clinical trial, as well as preclinical stage products, such as VXM04 to treat mesothelin; VXM06 for the treatment of Wilms Tumor Protein (WT1); VXM08 for Carcinoembryonic antigen (CEA); and VXM10 for PD-L1. It is also developing design-augmented (DA) biologics comprising DRT-102, a clinical-stage asset for spinal fusion; and DRT-101, a pre-clinical stage asset for osteoarthritis. In addition, the company distributes neurovascular intervention medical device and systems. The company was formerly known as OSR Holdings, Inc. and changed its name to OSR Health, Inc. in June 2026. OSR Health, Inc. was incorporated in 2020 and is based in Bellevue, Washington.
$OSRH stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in OSRH holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by OSRH's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
OSRH Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New OSRH patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to OSRH from public contracts
Source: USAspending.gov
Bull Case vs Bear Case
AI-generated from OSRH’s recent data — informational, not investment advice
